Golden Helix releases CancerKB 4.0

CancerKB 4.0 is now available to incorporate into cancer analysis workflows. CancerKB, Golden Helix's cancer biomarker database, is curated utilizing well-established cancer databases, biomarker frequency resources, literature review, and application of FDA, EMA, NCCN and other professional guidelines for all hematological cancers in their Drug Sensitivity Interpretations.

Golden Helix has also reviewed and synthesized the consensus from the NCCN guidelines, World Health Organization Blue Books, and International Consensus Classification publications to write prognosis and diagnostic interpretations for the most prevalent blood cancers and their subtypes, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, chronic lymphocytic leukemia, and chronic myelogenous leukemia. The focus is on capturing and harmonizing the diagnostic and prognostic information into report-ready interpretations for these tumor types sets.

Golden Helix started generating prognosis and diagnosis interpretations for the most prominent blood cancers because these are the most complex cancers to diagnose and provide accurate prognoses for. The curation team plans to continue working towards building out the diagnostic and prognostic interpretations available within CancerKB to cover all hematological cancers and solid tumors.

To support the additional drug sensitivity, diagnostic, and prognostic clinical interpretations for the hematological cancers, there are 150+ new biomarker summaries, nearly 1000 fully curated genes with tumor-specific outcomes and frequency interpretations, and close to 65,000 clinical trials to reference for patient therapeutic options and evidence.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>